C
Celltrion
Global biotech company that launched the world's first monoclonal antibody biosimilar
At a glance
- Status
- Listed
- Listing
- IPO 2005
Open roles
Celltrion in the Incheon ecosystem
The Celltrion office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
- KCKT&G Corporation
- VAVaxGen
Source: Dealroom Talent Intelligence.
Global footprint
Patents
171 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Investments and acquisitions
Disclosed deals where Celltrion was the backer or acquirer, 2021–2024. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.
4 deals across Celltrion's capital deployment.
Where the deals concentrate by sector, stage, and decade.
Where Celltrion deploys vs peers
Each axis is a Dealroom topic tag — picked from the cluster's most-tagged themes. Values are normalized per axis: the peer with the highest tag-coverage on that axis sits at the edge, others scale relative to them. Toggle between M&A, venture, or both.
Celltrion's portfolio, mapped.
See Celltrion on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.
Celltrion launches OMLYCLO, the first interchangeable biosimilar to Xolair, in the US
HEM Pharma raises 54B won to build second Sejong plant for Amway orders
